000286593 001__ 286593
000286593 005__ 20240229155126.0
000286593 0247_ $$2doi$$a10.3390/brainsci13121727
000286593 0247_ $$2pmid$$apmid:38137175
000286593 0247_ $$2pmc$$apmc:PMC10742051
000286593 0247_ $$2altmetric$$aaltmetric:157569625
000286593 037__ $$aDKFZ-2023-02810
000286593 041__ $$aEnglish
000286593 082__ $$a570
000286593 1001_ $$00000-0003-0136-4239$$aFarooq, Minaam$$b0
000286593 245__ $$aA Systematic Review of Nanomedicine in Glioblastoma Treatment: Clinical Efficacy, Safety, and Future Directions.
000286593 260__ $$aBasel$$bMDPI AG$$c2023
000286593 3367_ $$2DRIVER$$aarticle
000286593 3367_ $$2DataCite$$aOutput Types/Journal article
000286593 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1703765048_31546$$xReview Article
000286593 3367_ $$2BibTeX$$aARTICLE
000286593 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286593 3367_ $$00$$2EndNote$$aJournal Article
000286593 520__ $$a(1) Background: Glioblastoma (GBM) is categorized as a grade IV astrocytoma by the World Health Organization (WHO), representing the most aggressive and prevalent form of glioma. It presents a significant clinical challenge, with limited treatment options and poor prognosis. This systematic review evaluates the efficacy and safety of various nanotherapy approaches for GBM and explores future directions in tumor management. Nanomedicine, which involves nanoparticles in the 1-100 nm range, shows promise in improving drug delivery and targeting tumor cells. (2) Methods: Following PRISMA guidelines, a systematic search of databases including Google Scholar, NCBI PubMed, Cochrane Library, and ClinicalTrials.gov was conducted to identify clinical trials on GBM and nanomedicine. The primary outcome measures were median overall survival, progression-free survival, and quality of life assessed through Karnofsky performance scores. The safety profile was assessed by adverse events. (3) Results: The analysis included 225 GBM patients, divided into primary and recurrent sub-populations. Primary GBM patients had a median overall survival of 6.75 months, while recurrent GBM patients had a median overall survival of 9.7 months. The mean PFS period was 2.3 months and 3.92 months in primary GBM and recurrent GBM patients, respectively. Nanotherapy showed an improvement in quality of life, with KPS scores increasing after treatment in recurrent GBM patients. Adverse events were observed in 14.2% of patients. Notably, Bevacizumab therapy exhibited better survival outcomes but with a higher incidence of adverse events. (4) Conclusions: Nanotherapy offers a modest increase in survival with fewer severe side effects. It shows promise in improving the quality of life, especially in recurrent GBM patients. However, it falls short in terms of overall survival compared to Bevacizumab. The heterogeneous nature of treatment protocols and reporting methods highlights the need for standardized multicenter trials to further evaluate the potential of nanomedicine in GBM management.
000286593 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000286593 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286593 650_7 $$2Other$$aglioblastoma
000286593 650_7 $$2Other$$amolecular markers
000286593 650_7 $$2Other$$ananomedicine
000286593 650_7 $$2Other$$ananoparticles
000286593 650_7 $$2Other$$aquality of life
000286593 650_7 $$2Other$$atheranostics
000286593 7001_ $$00000-0002-9465-2506$$aScalia, Gianluca$$b1
000286593 7001_ $$00000-0002-1573-431X$$aUmana, Giuseppe E$$b2
000286593 7001_ $$0P:(DE-He78)d175d4ab09be0f7c46e1563679f341c7$$aParekh, Urja$$b3$$udkfz
000286593 7001_ $$00000-0002-1676-1512$$aNaeem, Faiza$$b4
000286593 7001_ $$aAbid, Sayeda Fatima$$b5
000286593 7001_ $$aKhan, Muhammad Hammad$$b6
000286593 7001_ $$aZahra, Shah Gul$$b7
000286593 7001_ $$aSarkar, Hrishikesh P$$b8
000286593 7001_ $$00000-0002-8392-2072$$aChaurasia, Bipin$$b9
000286593 773__ $$0PERI:(DE-600)2651993-8$$a10.3390/brainsci13121727$$gVol. 13, no. 12, p. 1727 -$$n12$$p1727$$tBrain Sciences$$v13$$x2076-3425$$y2023
000286593 909CO $$ooai:inrepo02.dkfz.de:286593$$pVDB
000286593 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d175d4ab09be0f7c46e1563679f341c7$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000286593 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000286593 9141_ $$y2023
000286593 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN SCI : 2022$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:57:08Z
000286593 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:57:08Z
000286593 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:57:08Z
000286593 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T14:57:08Z
000286593 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-26
000286593 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-26
000286593 9201_ $$0I:(DE-He78)B420-20160331$$kB420$$lGenominstabilität in Tumoren$$x0
000286593 980__ $$ajournal
000286593 980__ $$aVDB
000286593 980__ $$aI:(DE-He78)B420-20160331
000286593 980__ $$aUNRESTRICTED